Increased myelotoxicity of idarubicin: is there a pharmacological basis?: Results of a pharmacokinetic and an in vitro cytotoxicity study

Author： Kroschinsky Frank   Schleyer Eberhard   Renner Ulf   Schimming Claudia   Schimmelpfennig Christoph   Bornhäuser Martin   Illmer Thomas   Trümper Lorenz   Ehninger Gerhard   Schaich Markus  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.53, Iss.1, 2004-01, pp. : 61-67

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study

By Tedeschi Alessandra   Montillo Marco   Strocchi Elena   Cafro Anna   Tresoldi Elisabetta   Intropido Liliana   Nichelatti Michele   Marbello Laura   Baratè Claudia   Camaggi Carlo   Morra Enrica  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 6, 2007-06 ,pp. : 771-779

Springer Publishing Company

Access to resources Recommend Favorite

Study of the in vitro cytotoxicity testing of medical devices (Review)

By      

Biomedical Reports, Vol. 3, Iss. 5, 2015-01 ,pp. : 617-620

Science Publishers

Access to resources Recommend Favorite

Combination of Oral Idarubicin and Prednimustine in Advanced Breast Cancer: a Phase II Study

By Barnadas A.   Mendiola C.   Casado A.   Villar A.   Jimeno J.   Clerigue M.   Rosell R.   Diaz-Rubio E.   Cortes-Funes H.   Garci de Paredes M.  

European Journal of Cancer, Vol. 33, Iss. 2, 1997-02 ,pp. : 312-315

Elsevier

Access to resources Recommend Favorite

The in Vitro Radiosensitivity of Lymphocytes from Chronic Lymphocytic Leukaemia Using the Differential Staining Cytotoxicity (DiSC) Assay. II-Results on 40 Patients

By Hinkley Heather J.   Bosanquet Andrew G.  

International Journal of Radiation Biology, Vol. 61, Iss. 1, 1992-01 ,pp. : 111-121

Informa Healthcare

Access to resources Recommend Favorite

Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer

By Rudek Michelle  

Breast Cancer Research and Treatment, Vol. 139, Iss. 1, 2013-05 ,pp. : 135-143

Springer Publishing Company

Access to resources Recommend Favorite